Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Other Working Capital · Q2 FY2026 · quarter ended Jun 2026

Other working capital grows, but more slowly than its trailing trend

Q2 FY2026 other working capital of $48.82M rose 158.2% year over year, behind the +367.4% change in trailing-twelve-month other working capital. Sequentially, it rose 563.6% from the prior quarter. Over 3 fiscal years it compounded at +25.8% a year.

Context

  • Other working capital amounted to 12.9% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +158.2% toward the trailing-twelve-month pace of +367.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$48.82M+563.6% QoQ
Last fiscal yearDec 2025
$82.07M+57.2% YoY
LTMJun 2026
$118.35M+367.4% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+158.2%——
1 year+57.2%——
3-year CAGR+25.8%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
82.07M USD
Year-over-year change
+57.2%
4-year CAGR
+230.8%

Other Working Capital vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 other working capital of $118.35M is the 2nd largest of the 11 companies compared; the peer median is $5.13M.
  • Its year-over-year change of +367.4% is the 3rd highest of 11, against a peer median of -32.4%.
  • Other working capital amounts to 15.2% of revenue for AXSM, versus a peer median of 4.6%.
AXSM Competitors Peer median
Other Working Capital for AXSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$169M +44.8%-0.1%4.6%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$118.35M +367.4%+25.8%15.2%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$14.33M -85.4%+2.1%0.3%
DNLIDenali Therapeutics Inc.LTM Jun 2026$12.91M -128.5%—358.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$9.48M +2409.0%-50.7%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$9.11M +580.3%—1.1%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$9.09M +20.7%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4.68M -124.6%-55.3%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.51M -1220.1%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$1.16M +354.8%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1.11M -135.8%-4.7%5.5%
Peer median (excluding AXSM) $5.13M-32.4%-4.7%4.6%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
Deferred Income Tax00000
Stock-Based Compensation20.8M37.73M62.62M85.22M93.75M
Change in Working Capital324K23.67M(28.39M)33.9M(22.52M)
Accounts Receivables0(37.7M)(57.12M)(47.18M)(82.46M)
Inventory(6K)(5.28M)(8.16M)(2.44M)(15.67M)
Accounts Payables(355K)25.46M2.07M31.32M(6.46M)
Other Working Capital685K41.19M34.81M52.2M82.07M
Other Non-Cash Items974K4.83M53.1M31.73M9.48M
Operating Cash Flow(108.23M)(116.51M)(145.08M)(128.41M)(93.41M)
Capital Expenditures(308K)(702K)(582K)(270K)(480K)
Acquisitions (Net)0(53M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(308K)(53.7M)(582K)(270K)(480K)
Debt Repayment045M85M(990K)(7.75M)
Common Stock Issued7.44M243.76M258.75M40.78M126.27M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.69M(4.18M)(12.74M)18.05M(17.05M)
Financing Cash Flow11.13M284.58M331.01M57.84M101.47M
Effect of Forex Changes00000
Net Change in Cash(97.4M)114.37M185.35M(70.84M)7.58M
Free Cash Flow(108.53M)(117.21M)(145.66M)(128.68M)(93.89M)

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.